Published Research Summaries (click "Search" in Menu to filter)

Cannabis shows effectiveness for insomnia due to anxiety & depression

Using self-reported feedback on specific cannabis cultivars, this study wanted to determine if insomnia symptoms were improved in cannabis-using patients with anxiety and/or depression.

Meta-study: No evidence that adolescent cannabis use reduces brain volume

This study examined 16 qualified, cross-sectional, published studies that included 830 young adults aged 14 to 26 to determine if there was any correlation between adolescent cannabis use and global (GBV) or regional brain volume.

Study: Medical cannabis is effective for Multiple Sclerosis (MS) patients

"Users reported that cannabis is moderately to highly effective in treating several symptoms and that adverse effects are not generally severe."

2022 Study: Cannabis use over 12 months reduces PTSD symptom severity

This prospective study tracked PTSD symptoms and functioning every 3 months over a 12 month period. It was published in the journal Cannabis and Cannabinoid Research in April 2022.

CBDV Phase 1 Clinical Trial shows promise for juvenile RETT Syndrome

Fifty to ninety percent of children with Rett Syndrome RTT have epilepsy, which is often drug-resistant. This phase 1 trial looked at the effects and safety of CBDV isolate and was published in the journal Epilepsia in April 2022.

Review of medical cannabis effectiveness research

A review study of legal cannabinoid medical applications and associated research that was published in the journal Pharmacology in March 2022. They found evidence supporting the effectiveness of cannabinoid medicine for the treatment of more than nine different medical conditions.

Bisabolol and Caryophyllene show neuroprotective qualities

These two common cannabis terpenes were shown to have neuroprotective qualities in vitro (test tube in a lab). The research paper appears in the journal NeuroToxicology in May 2022.

Early cannabis use is not correlated with bipolar disorder in Finland

This study in Finland tracked 6,325 people from birth to age 33 (a single cohort born in 1986) to determine if early cannabis use was associated with adult bipolar disorder. It was published in the journal Addiction in March 2022.

CBD-A reduces stress and inflammation in cattle

CBD-A is the acidic precursor to CBD and is found in high amounts in raw industrial hemp flowers. This study examined the effects of feeding raw hemp flowers to cattle as a supplement.

30 Year Study: Daily cannabis users have lower heart rates

Resting heart rate can predict cardiovascular disease. This study examined data on 5,115 men and women over 30 years. The research was published in The American Journal of Medicine in March 2022.

CBD Isolate helps control anxiety in PTSD (nonsexual) patients

This randomized, parallel-group, double-blind, placebo-controlled trial study examined the anti-anxiety (anxiolytic) effects of a single 300mg dose of CBD administered to patients before a PTSD triggering event.

CBD inhibits growth of drug-resistant non-small cell lung cancer cells

Drug-resistant Non-Small Cell Lung Cancer has few treatments that are effective. This study examined the effects of CBD on this cancer type, and was published in February 2022 in the journal Cancers.

CBD promotes apoptosis of osteosarcoma cells

Osteosarcoma is a common type pf malignant bone tumor that often occurs in children, adolescents, and young adults. This study examined the anti-osteosarcoma effects of CBD in vitro and in vivo (mice) and was published in the American Journal of Translational Research in February 2022.

CBD and Naltrexone with chemotherapy shows improved effectiveness

This study focused on determining the effects of combining CBD and low‑dose naltrexone on the effectiveness of standard chemotherapy in cancer patients. It was published in the journal Oncology Reports in April 2022.

Oral cannabis helps reduce chronic refractory pain

This was a cross-sectional, observational analysis of chronic, treatment-resistant pain patients prescribed an oil formulation of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) over a minimum 3-month duration. It was published in Medical Cannabis and Cannabinoids in February 2022.

Cannabinoids and cancer review study

This review study of research on cannabinoids and cancer was published in March 2022 in the journal Pharmaceutical Medicine. It highlights positive results in studies dating back to 1975.

CBD shows antitumor activity in human pancreatic tumor cells

This study focused on determining the anticancer activity of a specific CBD-dominant cannabis extract on human pancreatic tumor cell lines, and was published in the journal Molecules in February 2022.

Cannabis can help reduce gynecological pain

This review study summarizes research published between 1990 and 2021 on the effectiveness of cannabinoid products at relieving gynecological pain. It was published in the journal Obstetrics and Gynecology in February 2022.

1 … 10 11 12 13 14 … 21

ads:

WARNING: Everyone has unique biochemistry, preexisting conditions, and mental state. Almost all medicinal and psychotropic products can cause adverse side effects in some people. The same is true with cannabinoid products, especially when they contain psychotropic cannabinoids like THC. Be very careful. Reported or statistically implied adverse effects include, but are not limited to: cannabis hyperemesis syndrome (CHS), adverse cardiovascular events (stroke, heart attack), arrhythmia, psychosis, and addiction (cannabis use disorder, or CUD).

Your cart is currently empty.

Enable cookies to use the shopping cart

t: e

(-)

Item Quantity

Special instructions